Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 1;33(1):1-6.
doi: 10.1097/GCO.0000000000000675.

PARP inhibitors in the treatment of ovarian cancer: a review

Christina R Washington  1 , Kathleen N Moore
Affiliations
Review

PARP inhibitors in the treatment of ovarian cancer: a review

Christina R Washington et al. Curr Opin Obstet Gynecol. .

Abstract

Purpose of review: This article will review recent changes in the standard of care for olaparib, niraparib, and rucaparib, as well as ongoing trials evaluating this class of drugs in combination with antiangiogenic agents and PD-1/PD-L1 inhibitors.

Recent findings: Niraparib received FDA approval for use in patients with complete response or partial response to first-line platinum-based chemotherapy regardless of BRCAm or HRD status that was received in April 2020. FDA approval was received for olaparib in combination with bevacizamab for epithelial ovarian cancer patients with complete response/partial response to first-line chemotherapy and bevacizumab and g/sBRCA and/or genomic instability by Myriad myChoice CDx in May 2020.

Summary: In the last year, treatment with PARPi has extended to not only include BRCAm and HRD-deficient patients but also have shown improvement in outcomes in HRD-proficient patients. With these advancements, more patients can access these agents and receive benefit. In the upcoming years, it will be exciting to see the potential benefit when PARPs are added to other angiogenic antagonists and immunotherapy agents.

Trial registration: ClinicalTrials.gov NCT02470585.

PubMed Disclaimer

References

    1. Society, A.C. Key Statistics for ovarian cancer, 2020. 2020 [08/15/2020]; Available from: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html . [Accessed 15 August 2020]
    1. Walsh CS. Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol 2015; 137:343–350.
    1. Wang S SK, XY., Feng B, et al. , Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models [abstract]. Proceedings of the American Association for Cancer Research Annual Meeting; 2018 April 14-18; Chicago, IL. Philadelphia (PA): AACR, 2006, 2018. Abstract #1724.
    1. Sato H, Niimi A, Yasuhara T, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun 2017; 8:1751.
    1. Hollebecque A, Meyer T, Moore KN, et al. An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. J Clin Oncol 2017; 35: (suppl; abstr 5504): 100.

MeSH terms

Substances

Associated data